{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tumor+necrosis+factor&page=8",
    "query": {
      "intervention": "tumor necrosis factor",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 339,
    "total_pages": 34,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tumor+necrosis+factor&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tumor+necrosis+factor&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-11T11:51:03.016Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06125197",
      "title": "Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "TILT-123",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KEYTRUDA®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TILT Biotherapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2024-07-23",
      "completion_date": "2026-05-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 2,
      "location_summary": "Newport Beach, California • Santa Monica, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06125197"
    },
    {
      "nct_id": "NCT02464878",
      "title": "Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant",
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Alpha 1-Antitrypsin",
          "type": "DRUG"
        },
        {
          "name": "Islet Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-01",
      "completion_date": "2022-12",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02464878"
    },
    {
      "nct_id": "NCT02031211",
      "title": "TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "CRPS",
        "Chronic Regional Pain Syndrome"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "FEMALE",
        "summary": "10 Years to 17 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2014-06",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2016-10-14",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02031211"
    },
    {
      "nct_id": "NCT01358578",
      "title": "Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "secukinumab (AIN457)",
          "type": "DRUG"
        },
        {
          "name": "etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1306,
      "start_date": "2011-06",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01358578"
    },
    {
      "nct_id": "NCT06651281",
      "title": "Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease",
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Tulisokibart",
          "type": "DRUG"
        },
        {
          "name": "Placebo to tulisokibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1380,
      "start_date": "2024-11-25",
      "completion_date": "2037-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 12,
      "location_summary": "Bristol, Connecticut • Ypsilanti, Michigan • Liberty, Missouri + 8 more",
      "locations": [
        {
          "city": "Bristol",
          "state": "Connecticut"
        },
        {
          "city": "Ypsilanti",
          "state": "Michigan"
        },
        {
          "city": "Liberty",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Garland",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06651281"
    },
    {
      "nct_id": "NCT00421174",
      "title": "Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumonia",
        "Idiopathic Pneumonia Syndrome"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2007-08",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 12,
      "location_summary": "Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00421174"
    },
    {
      "nct_id": "NCT00046904",
      "title": "Etanercept in Treating Cancer-Related Cachexia and Anorexia in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anorexia",
        "Cachexia",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "etanercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-05-05",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 19,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00046904"
    },
    {
      "nct_id": "NCT03331393",
      "title": "The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Non-interventional",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 265,
      "start_date": "2017-03-16",
      "completion_date": "2019-01-17",
      "has_results": false,
      "last_update_posted_date": "2022-07-06",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 7,
      "location_summary": "Beverly Hills, California • Gainesville, Georgia • Coeur d'Alene, Idaho + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Eagan",
          "state": "Minnesota"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03331393"
    },
    {
      "nct_id": "NCT02471144",
      "title": "Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Severe Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "Experimental : Secukinumab low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Experimental: Secukinumab high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Comparator: Secukinumab Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Active Comparator: Etanercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 162,
      "start_date": "2015-09-29",
      "completion_date": "2023-03-30",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02471144"
    },
    {
      "nct_id": "NCT00195494",
      "title": "Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 542,
      "start_date": "2004-11",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2012-09-05",
      "last_synced_at": "2026-10-11T11:51:03.016Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00195494"
    }
  ]
}